{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:11:03Z","timestamp":1795039863055,"version":"4.10.2"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41380-025-02939-9","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:42:42Z","timestamp":1741250562000},"page":"2783-2798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Neuroinflammatory fluid biomarkers in patients with Alzheimer\u2019s disease: a systematic literature review"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-1630","authenticated-orcid":false,"given":"Michael T.","family":"Heneka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar Anil","family":"Chandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-7047","authenticated-orcid":false,"given":"Julie","family":"Hviid Hahn-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2561-2308","authenticated-orcid":false,"given":"Marie A.","family":"Bentsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2939_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","volume":"118","author":"C Duyckaerts","year":"2009","unstructured":"Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5\u201336.","journal-title":"Acta Neuropathol"},{"key":"2939_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13311-021-01146-y","volume":"19","author":"JA Trejo-Lopez","year":"2022","unstructured":"Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer\u2019s disease. Neurotherapeutics. 2022;19:173\u201385.","journal-title":"Neurotherapeutics"},{"key":"2939_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.14283\/jpad.2021.23","volume":"8","author":"AP Porsteinsson","year":"2021","unstructured":"Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer\u2019s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371\u201386.","journal-title":"J Prev Alzheimers Dis"},{"key":"2939_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR Jr., Morris JC, Sperling R, Fr\u00f6lich L, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9:60.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"2939_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/imcb.12301","volume":"98","author":"A Webers","year":"2020","unstructured":"Webers A, Heneka MT, Gleeson PA. The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer\u2019s disease. Immunol Cell Biol. 2020;98:28\u201341.","journal-title":"Immunol Cell Biol"},{"key":"2939_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000211873","volume":"22","author":"O Fischer","year":"1907","unstructured":"Fischer O. Miliare nekrosen mit drusigen wucherungen der neuro-fibrillen, eine regelm\u00e4ssige ver\u00e4nderung der hirnrinde bei. Monatsschr Psychiatr Neurol. 1907;22:361.","journal-title":"Monatsschr Psychiatr Neurol"},{"key":"2939_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000283480","volume":"7","author":"P Eikelenboom","year":"2010","unstructured":"Eikelenboom P, Van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, Van Gool WA. Neuroinflammation\u2013an early event in both the history and pathogenesis of Alzheimer\u2019s disease. Neurodegener Dis. 2010;7:38\u201341.","journal-title":"Neurodegener Dis"},{"key":"2939_CR9","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli RC, Sierra A, Stevens B, Tremblay ME, Aguzzi A, Ajami B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron. 2022;110:3458\u201383.","journal-title":"Neuron"},{"key":"2939_CR10","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1172\/JCI90606","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus H, Heneka MT. Microglia in Alzheimer\u2019s disease. J Clin Invest. 2017;127:3240\u20139.","journal-title":"J Clin Invest"},{"key":"2939_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","volume":"24","author":"C Escartin","year":"2021","unstructured":"Escartin C, Galea E, Lakatos A, O\u2019Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24:312\u201325.","journal-title":"Nat Neurosci"},{"key":"2939_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1620\/tjem.174.295","volume":"174","author":"H Akiyama","year":"1994","unstructured":"Akiyama H. Inflammatory response in Alzheimer\u2019s disease. Tohoku J Exp Med. 1994;174:295\u2013303.","journal-title":"Tohoku J Exp Med"},{"key":"2939_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer\u2019s disease. Neurobiol Aging. 2000;21:383\u2013421.","journal-title":"Neurobiol Aging"},{"key":"2939_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54:412\u201336.","journal-title":"Nat Genet"},{"key":"2939_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2174\/1567205018666211105140732","volume":"18","author":"X Liang","year":"2021","unstructured":"Liang X, Wu H, Colt M, Guo X, Pluimer B, Zeng J, et al. Microglia and its genetics in Alzheimer\u2019s disease. Curr Alzheimer Res. 2021;18:676\u201388.","journal-title":"Curr Alzheimer Res"},{"key":"2939_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1212\/WNL.47.2.425","volume":"47","author":"PL McGeer","year":"1996","unstructured":"McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer\u2019s disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425\u201332.","journal-title":"Neurology"},{"key":"2939_CR17","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/S1473-3099(21)00144-4","volume":"21","author":"PN Sipil\u00e4","year":"2021","unstructured":"Sipil\u00e4 PN, Heikkil\u00e4 N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, et al. Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort. Lancet Infect Dis. 2021;21:1557\u201367.","journal-title":"Lancet Infect Dis"},{"key":"2939_CR18","doi-asserted-by":"publisher","first-page":"e2235648","DOI":"10.1001\/jamanetworkopen.2022.35648","volume":"5","author":"J Luo","year":"2022","unstructured":"Luo J, Thomassen JQ, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Frikke-Schmidt R. Blood leukocyte counts in Alzheimer disease. JAMA Netw Open. 2022;5:e2235648.","journal-title":"JAMA Netw Open"},{"key":"2939_CR19","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across braak stages. Nat Med. 2021;27:1592\u20139.","journal-title":"Nat Med"},{"key":"2939_CR20","doi-asserted-by":"publisher","first-page":"45s","DOI":"10.2967\/jnumed.121.263200","volume":"63","author":"JC Masdeu","year":"2022","unstructured":"Masdeu JC, Pascual B, Fujita M. Imaging neuroinflammation in neurodegenerative disorders. J Nucl Med. 2022;63:45s\u201352s.","journal-title":"J Nucl Med"},{"key":"2939_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4172\/2161-0460.1000434","volume":"8","author":"T Watermeyer","year":"2018","unstructured":"Watermeyer T, Raymont V, Ritchie K. Neuroinflammation in preclinical Alzheimer\u2019s disease: a review of current evidence. J Alzheimers Dis Parkinsonism. 2018;8:434.","journal-title":"J Alzheimers Dis Parkinsonism"},{"key":"2939_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2021.12.016","volume":"110","author":"F Brosseron","year":"2022","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Gonz\u00e1lez PG, McManus RM, et al. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer\u2019s disease. Neuron. 2022;110:1009\u201322.e1004","journal-title":"Neuron"},{"key":"2939_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.10265","volume":"52","author":"R Schmidt","year":"2002","unstructured":"Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol. 2002;52:168\u201374.","journal-title":"Ann Neurol"},{"key":"2939_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2019.01.002","volume":"50","author":"S Bradburn","year":"2019","unstructured":"Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: a meta-analysis. Ageing Res Rev. 2019;50:1\u20138.","journal-title":"Ageing Res Rev"},{"key":"2939_CR25","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/brain\/awx120","volume":"140","author":"P Parbo","year":"2017","unstructured":"Parbo P, Ismail R, Hansen KV, Amidi A, M\u00e5rup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer\u2019s disease. Brain. 2017;140:2002\u201311.","journal-title":"Brain"},{"key":"2939_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-37","volume":"5","author":"JW Lee","year":"2008","unstructured":"Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation. 2008;5:37.","journal-title":"J Neuroinflammation"},{"key":"2939_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/jnc.13411","volume":"136","author":"MR Minter","year":"2016","unstructured":"Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer\u2019s disease. J Neurochem. 2016;136:457\u201374.","journal-title":"J Neurochem"},{"key":"2939_CR28","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/brain\/awv081","volume":"138","author":"N Maphis","year":"2015","unstructured":"Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138:1738\u201355.","journal-title":"Brain"},{"key":"2939_CR29","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29:1775\u201381.","journal-title":"Nat Med"},{"key":"2939_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature. 2017;552:355\u201361.","journal-title":"Nature"},{"key":"2939_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669\u201373.","journal-title":"Nature"},{"key":"2939_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41066-9","volume":"13","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Chen T, Hu J. Genetic analysis of potential biomarkers and therapeutic targets in neuroinflammation from sporadic Creutzfeldt-Jakob disease. Sci Rep. 2023;13:14122.","journal-title":"Sci Rep"},{"key":"2939_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41582-019-0231-z","volume":"15","author":"F Bright","year":"2019","unstructured":"Bright F, Werry EL, Dobson-Stone C, Piguet O, Ittner LM, Halliday GM, et al. Neuroinflammation in frontotemporal dementia. Nat Rev Neurol. 2019;15:540\u201355.","journal-title":"Nat Rev Neurol"},{"key":"2939_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11481-009-9176-0","volume":"4","author":"JK Lee","year":"2009","unstructured":"Lee JK, Tran T, Tansey MG. Neuroinflammation in Parkinson\u2019s disease. J Neuroimmune Pharmacol. 2009;4:419\u201329.","journal-title":"J Neuroimmune Pharmacol"},{"key":"2939_CR35","first-page":"e12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement. 2023;9:e12385.","journal-title":"Alzheimers Dement"},{"key":"2939_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fimmu.2020.00456","volume":"11","author":"H Hampel","year":"2020","unstructured":"Hampel H, Caraci F, Cuello AC, Caruso G, Nistic\u00f2 R, Corbo M, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer\u2019s disease. Front Immunol. 2020;11:456.","journal-title":"Front Immunol"},{"key":"2939_CR37","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","volume":"95","author":"JL Ebenau","year":"2020","unstructured":"Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. 2020;95:e46\u2013e58.","journal-title":"Neurology"},{"key":"2939_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"2939_CR39","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"2939_CR40","first-page":"5","volume":"51","author":"MH Kazakova","year":"2009","unstructured":"Kazakova MH, Sarafian VS. YKL-40\u2013a novel biomarker in clinical practice? Folia Med. 2009;51:5\u201314.","journal-title":"Folia Med"},{"key":"2939_CR41","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/rheumatology\/32.11.949","volume":"32","author":"JS Johansen","year":"1993","unstructured":"Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol. 1993;32:949\u201355.","journal-title":"Br J Rheumatol"},{"key":"2939_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22:530\u201346.","journal-title":"Brain Pathol"},{"key":"2939_CR43","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/brainsci13101364","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Tian J, Ni J, Wei M, Li T, Shi J. Peripheral blood and cerebrospinal fluid levels of YKL-40 in Alzheimer\u2019s disease: a systematic review and meta-analysis. Brain Sci. 2023;13:1364.","journal-title":"Brain Sci"},{"key":"2939_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:903\u201312.","journal-title":"Biol Psychiatry"},{"key":"2939_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","volume":"23","author":"M Colonna","year":"2023","unstructured":"Colonna M. The biology of TREM receptors. Nat Rev Immunol. 2023;23:580\u201394.","journal-title":"Nat Rev Immunol"},{"key":"2939_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","volume":"14","author":"M Suarez-Calvet","year":"2019","unstructured":"Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-\u03b2 pathology. Mol Neurodegener. 2019;14:1.","journal-title":"Mol Neurodegener"},{"key":"2939_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1750-3639.1994.tb00838.x","volume":"4","author":"LF Eng","year":"1994","unstructured":"Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4:229\u201337.","journal-title":"Brain Pathol"},{"key":"2939_CR48","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/biom11091361","volume":"11","author":"AM Jurga","year":"2021","unstructured":"Jurga AM, Paleczna M, Kadluczka J, Kuter KZ. Beyond the GFAP-astrocyte protein markers in the brain. Biomolecules. 2021;11:1361.","journal-title":"Biomolecules"},{"key":"2939_CR49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh S-H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.","journal-title":"Transl Neurodegener"},{"key":"2939_CR50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/brainsci11020215","volume":"11","author":"DA McGrowder","year":"2021","unstructured":"McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: current evidence and future perspectives. Brain Sci. 2021;11:215.","journal-title":"Brain Sci"},{"key":"2939_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00281-017-0662-9","volume":"40","author":"BP Morgan","year":"2018","unstructured":"Morgan BP. Complement in the pathogenesis of Alzheimer\u2019s disease. Semin Immunopathol. 2018;40:113\u201324.","journal-title":"Semin Immunopathol"},{"key":"2939_CR52","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"2939_CR53","doi-asserted-by":"crossref","unstructured":"Kenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JPT, (ed). Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration and John Wiley & Sons Ltd: Hoboken; 2019. pp. 33\u201365.","DOI":"10.1002\/9781119536604.ch3"},{"key":"2939_CR54","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jalz.2019.09.001","volume":"16","author":"A Antonell","year":"2020","unstructured":"Antonell A, Tort-Merino A, Rios J, Balasa M, Borrego-Ecija S, Auge JM, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement. 2020;16:262\u201372.","journal-title":"Alzheimers Dement"},{"key":"2939_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12:2.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR56","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/biom10040497","volume":"10","author":"S Abu-Rumeileh","year":"2020","unstructured":"Abu-Rumeileh S, Oeckl P, Baiardi S, Halbgebauer S, Steinacker P, Capellari S, et al. CSF ubiquitin levels are higher in Alzheimer\u2019s disease than in frontotemporal dementia and reflect the molecular subtype in prion disease. Biomolecules. 2020;10:497.","journal-title":"Biomolecules"},{"key":"2939_CR57","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867\u2013e877.","journal-title":"Neurology"},{"key":"2939_CR58","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316.","journal-title":"Brain"},{"key":"2939_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-2012-120787","volume":"33","author":"B Olsson","year":"2013","unstructured":"Olsson B, Hertze J, Lautner R, Zetterberg H, N\u00e4gga K, H\u00f6glund K, et al. Microglial markers are elevated in the prodromal phase of Alzheimer\u2019s disease and vascular dementia. J Alzheimers Dis. 2013;33:45\u201353.","journal-title":"J Alzheimers Dis"},{"key":"2939_CR60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-020-00657-8","volume":"12","author":"UD Teitsdottir","year":"2020","unstructured":"Teitsdottir UD, Jonsdottir MK, Lund SH, Darreh-Shori T, Snaedal J, Petersen PH. Association of glial and neuronal degeneration markers with Alzheimer\u2019s disease cerebrospinal fluid profile and cognitive functions. Alzheimers Res Ther. 2020;12:92.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-022-01118-0","volume":"15","author":"F Brosseron","year":"2023","unstructured":"Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Kolbe CC, Wolfsgruber S, et al. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer\u2019s disease: results from the DELCODE study. Alzheimers Res Ther. 2023;15:13.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-022-01051-2","volume":"14","author":"S Prins","year":"2022","unstructured":"Prins S, de Kam ML, Teunissen CE, Groeneveld GJ. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:106.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR63","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neurobiolaging.2018.10.022","volume":"74","author":"BS Rauchmann","year":"2019","unstructured":"Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, Alzheimer\u2019s Disease Neuroimaging Initiative. CSF soluble TREM2 as a measure of immune response along the Alzheimer\u2019s disease continuum. Neurobiol Aging. 2019;74:182\u201390.","journal-title":"Neurobiol Aging"},{"key":"2939_CR64","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ana.26465","volume":"92","author":"BS Rauchmann","year":"2022","unstructured":"Rauchmann BS, Brendel M, Franzmeier N, Trappmann L, Zaganjori M, Ersoezlue E, et al. Microglial activation and connectivity in Alzheimer disease and aging. Ann Neurol. 2022;92:768\u201381.","journal-title":"Ann Neurol"},{"key":"2939_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.03.003","volume":"319","author":"LM Bekris","year":"2018","unstructured":"Bekris LM, Khrestian M, Dyne E, Shao Y, Pillai JA, Rao SM, et al. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. J Neuroimmunol. 2018;319:19\u201327.","journal-title":"J Neuroimmunol"},{"key":"2939_CR66","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-019-0545-5","volume":"11","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Suarez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, et al. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther. 2019;11:94.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR67","doi-asserted-by":"publisher","first-page":"887498","DOI":"10.3389\/fnagi.2022.887498","volume":"14","author":"T Parvizi","year":"2022","unstructured":"Parvizi T, Konig T, Wurm R, Silvaieh S, Altmann P, Klotz S, et al. Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer\u2019s disease. Front Aging Neurosci. 2022;14:887498.","journal-title":"Front Aging Neurosci"},{"key":"2939_CR68","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67:481\u20138.","journal-title":"J Alzheimers Dis"},{"key":"2939_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11:27.","journal-title":"Transl Psychiatry"},{"key":"2939_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/alz.12614","volume":"19","author":"H Stocker","year":"2023","unstructured":"Stocker H, Beyer L, Perna L, Rujescu D, Holleczek B, Beyreuther K, et al. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer\u2019s disease risk: Results from a prospective cohort followed over 17 years. Alzheimers Dement. 2023;19:25\u201335.","journal-title":"Alzheimers Dement"},{"key":"2939_CR71","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79:1250\u20139.","journal-title":"JAMA Neurol"},{"key":"2939_CR72","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp-2021-328547","volume":"93","author":"P Oeckl","year":"2022","unstructured":"Oeckl P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, Diehl-Schmid J, Grimmer T, et al. Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry. 2022;93:659\u201367.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2939_CR73","doi-asserted-by":"publisher","first-page":"577744","DOI":"10.1016\/j.jneuroim.2021.577744","volume":"361","author":"G Katsipis","year":"2021","unstructured":"Katsipis G, Tzekaki EE, Tsolaki M, Pantazaki AA. Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer\u2019s disease and its correlation with neuroinflammation and apoptosis. J Neuroimmunol. 2021;361:577744.","journal-title":"J Neuroimmunol"},{"key":"2939_CR74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40035-021-00275-w","volume":"10","author":"N Zhu","year":"2021","unstructured":"Zhu N, Santos-Santos M, Ill\u00e1n-Gala I, Montal V, Estell\u00e9s T, Barroeta I, et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Transl Neurodegener. 2021;10:50.","journal-title":"Transl Neurodegener"},{"key":"2939_CR75","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/acn3.51109","volume":"7","author":"JA Pillai","year":"2020","unstructured":"Pillai JA, Bena J, Bebek G, Bekris LM, Bonner-Jackson A, Kou L, et al. Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2020;7:1225\u201339.","journal-title":"Ann Clin Transl Neurol"},{"key":"2939_CR76","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Dor\u00e9 V, et al. Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19:1117\u201334.","journal-title":"Alzheimers Dement"},{"key":"2939_CR77","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/JAD-171131","volume":"63","author":"A Julian","year":"2018","unstructured":"Julian A, Rioux-Bilan A, Ragot S, Krolak-Salmon P, Berrut G, Dantoine T, et al. Blood inflammatory mediators and cognitive decline in Alzheimer\u2019s disease: a two years longitudinal study. J Alzheimers Dis. 2018;63:87\u201392.","journal-title":"J Alzheimers Dis"},{"key":"2939_CR78","doi-asserted-by":"publisher","first-page":"686","DOI":"10.14283\/jpad.2023.109","volume":"10","author":"M Kiraly","year":"2023","unstructured":"Kiraly M, Foss JF, Giordano T. Neuroinflammation, its role in Alzheimer\u2019s disease and therapeutic strategie. J Prev Alzheimers Dis. 2023;10:686\u201398.","journal-title":"J Prev Alzheimers Dis"},{"key":"2939_CR79","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463\u20136.","journal-title":"Curr Opin HIV AIDS"},{"key":"2939_CR80","doi-asserted-by":"publisher","first-page":"401","DOI":"10.14283\/jpad.2023.54","volume":"10","author":"A Bieger","year":"2023","unstructured":"Bieger A, Rocha A, Bellaver B, Machado L, Da Ros L, Borelli WV, et al. Neuroinflammation biomarkers in the AT(N) framework across the Alzheimer\u2019s disease continuum. J Prev Alzheimers Dis. 2023;10:401\u201317.","journal-title":"J Prev Alzheimers Dis"},{"key":"2939_CR81","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137.","journal-title":"Nat Med"},{"key":"2939_CR82","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.arr.2023.102046","volume":"91","author":"A Gaur","year":"2023","unstructured":"Gaur A, Rivet L, Mah E, Bawa KK, Gallagher D, Herrmann N, et al. Novel fluid biomarkers for mild cognitive impairment: a systematic review and meta-analysis. Ageing Res Rev. 2023;91:102046.","journal-title":"Ageing Res Rev"},{"key":"2939_CR83","doi-asserted-by":"publisher","first-page":"1069411","DOI":"10.3389\/fneur.2023.1069411","volume":"14","author":"P Kivis\u00e4kk","year":"2023","unstructured":"Kivis\u00e4kk P, Carlyle BC, Sweeney T, Trombetta BA, LaCasse K, El-Mufti L, et al. Plasma biomarkers for diagnosis of Alzheimer\u2019s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front Neurol. 2023;14:1069411.","journal-title":"Front Neurol"},{"key":"2939_CR84","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7:59.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR85","doi-asserted-by":"publisher","first-page":"e208075","DOI":"10.1212\/WNL.0000000000208075","volume":"102","author":"MP Pase","year":"2024","unstructured":"Pase MP, Himali JJ, Puerta R, Beiser AS, Gonzales MM, Satizabal CL, et al. Association of plasma YKL-40 with MRI, CSF, and cognitive markers of brain health and dementia. Neurology. 2024;102:e208075.","journal-title":"Neurology"},{"key":"2939_CR86","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13195-022-01039-y","volume":"14","author":"AHYS Hok","year":"2022","unstructured":"Hok AHYS, Hoozemans JJM, Hu WT, Wouters D, Howell JC, R\u00e1bano A, et al. YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer\u2019s disease and frontotemporal lobar degeneration. Alzheimers Res Ther. 2022;14:100.","journal-title":"Alzheimers Res Ther"},{"key":"2939_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0742-9","volume":"16","author":"Y Deming","year":"2016","unstructured":"Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurol. 2016;16:217.","journal-title":"BMC Neurol"},{"key":"2939_CR88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13024-020-00374-8","volume":"15","author":"LZ Ma","year":"2020","unstructured":"Ma LZ, Tan L, Bi YL, Shen XN, Xu W, Ma YH, et al. Dynamic changes of CSF sTREM2 in preclinical Alzheimer\u2019s disease: the CABLE study. Mol Neurodegener. 2020;15:25.","journal-title":"Mol Neurodegener"},{"key":"2939_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02962-z","volume":"20","author":"MS Woo","year":"2023","unstructured":"Woo MS, Nilsson J, Therriault J, Rahmouni N, Brinkmalm A, Benedet AL, et al. 14-3-3 [Formula: see text]-reported early synaptic injury in Alzheimer\u2019s disease is independently mediated by sTREM2. J Neuroinflammation. 2023;20:278.","journal-title":"J Neuroinflammation"},{"key":"2939_CR90","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis. Cells. 2023;12:1309.","journal-title":"Cells"},{"key":"2939_CR91","doi-asserted-by":"publisher","first-page":"e2944","DOI":"10.1212\/WNL.0000000000012109","volume":"96","author":"B Bellaver","year":"2021","unstructured":"Bellaver B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, Rodriguez-Vieitez E, Nordberg A, et al. Astrocyte biomarkers in alzheimer disease: a systematic review and meta-analysis. Neurology. 2021;96:e2944\u2013e2955.","journal-title":"Neurology"},{"key":"2939_CR92","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2:e87\u2013e95.","journal-title":"Lancet Healthy Longev"},{"key":"2939_CR93","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","volume":"69","author":"XN Shen","year":"2023","unstructured":"Shen XN, Huang SY, Cui M, Zhao QH, Guo Y, Huang YY, et al. Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression. Clin Chem. 2023;69:411\u201321.","journal-title":"Clin Chem"},{"key":"2939_CR94","doi-asserted-by":"publisher","first-page":"835597","DOI":"10.3389\/fneur.2022.835597","volume":"13","author":"D Janigro","year":"2022","unstructured":"Janigro D, Mondello S, Posti JP, Unden J. GFAP and S100B: what you always wanted to know and never dared to ask. Front Neurol. 2022;13:835597.","journal-title":"Front Neurol"},{"key":"2939_CR95","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte biomarkers in Alzheimer\u2019s disease. Trends Mol Med. 2019;25:77\u201395.","journal-title":"Trends Mol Med"},{"key":"2939_CR96","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","volume":"68","author":"F Gao","year":"2023","unstructured":"Gao F, Dai L, Wang Q, Liu C, Deng K, Cheng Z, et al. Blood-based biomarkers for Alzheimer\u2019s disease: a multicenter-based cross-sectional and longitudinal study in China. Sci Bull. 2023;68:1800\u20138.","journal-title":"Sci Bull"},{"key":"2939_CR97","first-page":"e12492","volume":"15","author":"M Ally","year":"2023","unstructured":"Ally M, Sugarman MA, Zetterberg H, Blennow K, Ashton NJ, Karikari TK, et al. Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer\u2019s disease. Alzheimers Dement. 2023;15:e12492.","journal-title":"Alzheimers Dement"},{"key":"2939_CR98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/jnnp-2022-329663","volume":"94","author":"A O\u2019Connor","year":"2023","unstructured":"O\u2019Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston PSJ, et al. Plasma GFAP in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study. J Neurol Neurosurg Psychiatry. 2023;94:90\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2939_CR99","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/brain\/awae035","volume":"147","author":"P S\u00e1nchez-Juan","year":"2024","unstructured":"S\u00e1nchez-Juan P, Valeriano-Lorenzo E, Ruiz-Gonz\u00e1lez A, Pastor AB, Rodrigo Lara H, L\u00f3pez-Gonz\u00e1lez F, et al. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles. Brain. 2024;147:1667\u201379.","journal-title":"Brain"},{"key":"2939_CR100","doi-asserted-by":"publisher","first-page":"e2345175","DOI":"10.1001\/jamanetworkopen.2023.45175","volume":"6","author":"CS Aguzzoli","year":"2023","unstructured":"Aguzzoli CS, Ferreira PC, Povala G, Ferrari-Souza JP, Bellaver B, Katz CS, et al. Neuropsychiatric symptoms and microglial activation in patients with Alzheimer disease. JAMA Netw Open. 2023;6:e2345175\u2013e2345175.","journal-title":"JAMA Netw Open"},{"key":"2939_CR101","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/ejn.15613","volume":"55","author":"D Gouilly","year":"2022","unstructured":"Gouilly D, Saint\u2010Aubert L, Ribeiro MJ, Salabert AS, Tauber C, P\u00e9ran P, et al. Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer\u2019s disease: an update. Eur J Neurosci. 2022;55:1322\u201343.","journal-title":"Eur J Neurosci"},{"key":"2939_CR102","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41586-023-06802-1","volume":"624","author":"HS Oh","year":"2023","unstructured":"Oh HS, Rutledge J, Nachun D, P\u00e1lovics R, Abiose O, Moran-Losada P, et al. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023;624:164\u201372.","journal-title":"Nature"},{"key":"2939_CR103","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ana.26817","volume":"95","author":"HE Dark","year":"2024","unstructured":"Dark HE, Paterson C, Daya GN, Peng Z, Duggan MR, Bilgel M, et al. Proteomic indicators of health predict Alzheimer\u2019s disease biomarker levels and dementia risk. Ann Neurol. 2024;95:260\u201373.","journal-title":"Ann Neurol"},{"key":"2939_CR104","doi-asserted-by":"publisher","unstructured":"Cruchaga C, Western D, Timsina J, Wang L, Wang C, Yang C et al. Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and informs causal proteins for Alzheimer\u2019s disease. Res Sq. 2023:rs.3.rs-2814616. https:\/\/doi.org\/10.21203\/rs.3.rs-2814616\/v1.","DOI":"10.21203\/rs.3.rs-2814616\/v1"},{"key":"2939_CR105","doi-asserted-by":"publisher","first-page":"eabq5923","DOI":"10.1126\/scitranslmed.abq5923","volume":"15","author":"YJ Sung","year":"2023","unstructured":"Sung YJ, Yang C, Norton J, Johnson M, Fagan A, Bateman RJ, et al. Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer\u2019s disease. Sci Transl Med. 2023;15:eabq5923.","journal-title":"Sci Transl Med"},{"key":"2939_CR106","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s43587-022-00300-1","volume":"2","author":"M Del Campo","year":"2022","unstructured":"Del Campo M, Peeters CFW, Johnson ECB, Vermunt L, Hok AHYS, van Nee M, et al. CSF proteome profiling across the Alzheimer\u2019s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2:1040\u201353.","journal-title":"Nat Aging"},{"key":"2939_CR107","doi-asserted-by":"publisher","unstructured":"Tijms BM, Vromen EM, Mjaavatten O, Holstege H, Reus LM, Lee SVD et al. Large-scale cerebrospinal fluid proteomic analysis in Alzheimer\u2019s disease patients reveals five molecular subtypes with distinct genetic risk profiles. medRxiv. https:\/\/doi.org\/10.1101\/2023.05.10.23289793.","DOI":"10.1101\/2023.05.10.23289793"},{"key":"2939_CR108","doi-asserted-by":"publisher","first-page":"eabo6764","DOI":"10.1126\/sciadv.abo6764","volume":"8","author":"Y Iturria-Medina","year":"2022","unstructured":"Iturria-Medina Y, Adewale Q, Khan AF, Ducharme S, Rosa-Neto P, O\u2019Donnell K, et al. Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer\u2019s disease progression and heterogeneity. Sci Adv. 2022;8:eabo6764.","journal-title":"Sci Adv"},{"key":"2939_CR109","doi-asserted-by":"publisher","first-page":"e072741","DOI":"10.1002\/alz.072741","volume":"19","author":"M del Campo","year":"2023","unstructured":"del Campo M, Quesada C, Vermunt L, Peeters CFW, Hok-A-Hin YS, den Braber A, et al. CSF proteome profiling reveals a protein panel detecting amyloidosis and progression to dementia in cognitively unimpaired individuals. Alzheimers Dement. 2023;19:e072741.","journal-title":"Alzheimers Dement"},{"key":"2939_CR110","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342.","journal-title":"Nat Rev Neurol"},{"key":"2939_CR111","doi-asserted-by":"publisher","first-page":"e1265","DOI":"10.1212\/WNL.0000000000200892","volume":"99","author":"F Piazza","year":"2022","unstructured":"Piazza F, Caminiti SP, Zedde M, Presotto L, DiFrancesco JC, Pascarella R, et al. Association of microglial activation with spontaneous ARIA-E and CSF levels of anti-A\u03b2 autoantibodies. Neurology. 2022;99:e1265\u2013e1277.","journal-title":"Neurology"},{"key":"2939_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03418-8","volume":"22","author":"X Wang","year":"2024","unstructured":"Wang X, Shi Z, Qiu Y, Sun D, Zhou H. Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC Med. 2024;22:192.","journal-title":"BMC Med"},{"key":"2939_CR113","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024;4:247\u201360.","journal-title":"Nat Aging"},{"key":"2939_CR114","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/alz.12745","volume":"19","author":"L Beyer","year":"2023","unstructured":"Beyer L, Stocker H, Rujescu D, Holleczek B, Stockmann J, Nabers A, et al. Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer\u2019s disease diagnosis within 17 years. Alzheimers Dement. 2023;19:1020\u20138.","journal-title":"Alzheimers Dement"},{"key":"2939_CR115","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","volume":"20","author":"W Pelkmans","year":"2024","unstructured":"Pelkmans W, Shekari M, Brugulat-Serrat A, S\u00e1nchez-Benavides G, Minguill\u00f3n C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression. Alzheimers Dement. 2024;20:483\u201393.","journal-title":"Alzheimers Dement"},{"key":"2939_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66211-w","volume":"14","author":"F Nabizadeh","year":"2024","unstructured":"Nabizadeh F, Seyedmirzaei H, Karami S. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer\u2019s disease: a longitudinal study. Sci Rep. 2024;14:15318.","journal-title":"Sci Rep"},{"key":"2939_CR117","doi-asserted-by":"publisher","first-page":"1407980","DOI":"10.3389\/fnagi.2024.1407980","volume":"16","author":"R Wang","year":"2024","unstructured":"Wang R, Zhan Y, Zhu W, Yang Q, Pei J. Association of soluble TREM2 with Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Front Aging Neurosci. 2024;16:1407980.","journal-title":"Front Aging Neurosci"},{"key":"2939_CR118","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s40120-023-00504-6","volume":"12","author":"AA Tahami Monfared","year":"2023","unstructured":"Tahami Monfared AA, Phan NTN, Pearson I, Mauskopf J, Cho M, Zhang Q, et al. A systematic review of clinical practice guidelines for Alzheimer\u2019s disease and strategies for future advancements. Neurol Ther. 2023;12:1257\u201384.","journal-title":"Neurol Ther"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02939-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:08:49Z","timestamp":1747721329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02939-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":118,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-02939-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MTH serves on scientific advisory boards for Alector, Dementia Discovery Fund, UK DRI, and T3D Therapeutics. He has received honoraria for consultations and\/or oral presentations from AC Immune, Biogen, Eisai, Novo Nordisk, and Roche. SG has served on scientific advisory boards for ADvantage Therapeutics, Alzheon, AmyriAD, Biogen Canada, Eisai Canada, Enigma, Lilly Canada, Lundbeck, Medesis, Roche Canada, Sharon Francis Foundation, and TauRx. SAC, JHH-P, and MAB are full-time employees of Novo Nordisk A\/S. HZ has served on scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Annexon, Apellis, Artery Therapeutics, Inc., AZTherapies, Inc., Cognition Therapeutics, Inc., Denali Therapeutics, Eisai, NervGen, Novo Nordisk, OptoCeutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, Inc., and Wave Life Sciences. He has given lectures in symposia sponsored by AlzeCure, Biogen, Cellectricon, Fujirebio, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). He is also a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council, supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397); the European Union\u2019s Horizon Europe research and innovation programme under grant agreement No 101053962; Swedish State Support for Clinical Research (#ALFGBG-71320); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer\u2019s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C); the Bluefield Project; Cure Alzheimer\u2019s Fund; the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor, Hj\u00e4rnfonden, Sweden (#FO2022-0270); the European Union\u2019s Horizon 2020 research and innovation programme under the Marie Sk\u0142odowska-Curie grant agreement No 860197 (MIRIADE); and the European Union Joint Programme \u2013 Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}